Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Giles

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Blood Cancer Journal|August 16, 2014
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemiaJ F Seymour, D W Kim, E Rubin, et al.
Leukemia|July 10, 2012
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemiaF J Giles, R T Swords, A Nagler, et al.
Leukemia & Lymphoma|July 28, 2016
Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of TechniqueF J Giles, C D Lord, E J Gaminarai, et al.
JCO Precision Oncology|September 11, 2019
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function MutationsB A Carneiro, K A Collier, R J Nagy, et al.
Leukemia|July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II studyF J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
ESMO Open|May 22, 2025
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancerD Mahalingam, A Saeed, S F Powell, et al.
Leukemia|February 21, 2017
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom studyA Hochhaus, T Masszi, F J Giles, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Leukemia|October 7, 2015
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st studyA Hochhaus, G Rosti, N C P Cross, et al.
Leukemia & Lymphoma|June 28, 2001
A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study F J Giles, J Shan, S H Advani, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Blood Cancer Journal|August 16, 2014
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemiaJ F Seymour, D W Kim, E Rubin, et al.
Leukemia|July 10, 2012
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemiaF J Giles, R T Swords, A Nagler, et al.
Leukemia & Lymphoma|July 28, 2016
Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of TechniqueF J Giles, C D Lord, E J Gaminarai, et al.
JCO Precision Oncology|September 11, 2019
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function MutationsB A Carneiro, K A Collier, R J Nagy, et al.
Leukemia|July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II studyF J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
ESMO Open|May 22, 2025
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancerD Mahalingam, A Saeed, S F Powell, et al.
Leukemia|February 21, 2017
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom studyA Hochhaus, T Masszi, F J Giles, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Leukemia|October 7, 2015
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st studyA Hochhaus, G Rosti, N C P Cross, et al.
Leukemia & Lymphoma|June 28, 2001
A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study F J Giles, J Shan, S H Advani, et al.
Pageof 13